Thursday, July 30

Browsing: Multitarget

Treatments

86 Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-Line (2L) Treatment of Patients With HR+/HER2–/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Updated Results From VIKTORIA-1

By NewsCancerMay 28, 20260

BackgroundThe PAM pathway drives breast cancer growth and mediates resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i). Combining PAM…

Support

87 Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-Line (2L) Treatment of Patients With HR+/HER2–/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Topline Results From VIKTORIA-1

By NewsCancerMay 27, 20260

BackgroundThe PAM pathway drives breast cancer growth and mediates resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i). Combining PAM…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Relapsed childhood cancers show genomic scars left by previous therapy

Introduction to BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma

Advancing Multidisciplinary Care and Health Equity in Metastatic Breast Cancer

Browsing: Multitarget

86 Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-Line (2L) Treatment of Patients With HR+/HER2–/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Updated Results From VIKTORIA-1

87 Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-Line (2L) Treatment of Patients With HR+/HER2–/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Topline Results From VIKTORIA-1

Relapsed childhood cancers show genomic scars left by previous therapy

Introduction to BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma

Advancing Multidisciplinary Care and Health Equity in Metastatic Breast Cancer

Linvoseltamab Data and Clinical Perspectives in Relapsed/Refractory Multiple Myeloma

Relapsed childhood cancers show genomic scars left by previous therapy

Introduction to BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma

Advancing Multidisciplinary Care and Health Equity in Metastatic Breast Cancer

Linvoseltamab Data and Clinical Perspectives in Relapsed/Refractory Multiple Myeloma

Latest Post

Relapsed childhood cancers show genomic scars left by previous therapy

Introduction to BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma

Advancing Multidisciplinary Care and Health Equity in Metastatic Breast Cancer

Subscribe to Updates

What's Hot

Browsing: Multitarget